Journal article
An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer
YC Lee, M Michael, JR Zalcberg
Expert Opinion on Investigational Drugs | TAYLOR & FRANCIS LTD | Published : 2015
Abstract
Introduction: The era of molecular-targeted agents, particularly bevacizumab and cetuximab, has revolutionized the treatment paradigm for metastatic colorectal cancer (mCRC). Amongst the multikinase inhibitors (MKIs) examined, regorafenib was the first to establish its role in mCRC. Despite its modest efficacy, this finding had reignited interest in exploring MKIs with the hope of maximizing their therapeutic potential in mCRC.Areas covered: This review summarizes the previous studies of MKIs in mCRC, targeting two signaling pathways activated through vascular endothelial growth factor receptors and epidermal growth factor receptors. The article provides discussion with a focus on: the chall..
View full abstractGrants
Funding Acknowledgements
M Michael has received funding from Pfizer Inc., Novartis, and Roche. He is also a member of the advisory board for Novartis, Pfizer Inc., Eli Lilly and Company, Ipsen Ltd and Sanofi Aventis. J Zalcberg has received research and/or travel support from Roche, Bayer Healthcare, Merck Serono, Amgen Inc., and Sanofi Aventis. He has also received honoraria from speaking and/or is a member of the advisory board from Roche, Bayer Healthcare, Amgen Inc., and Novartis. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.